EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

NCT ID: NCT06894173

Last Updated: 2025-03-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-03

Study Completion Date

2026-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to describe the percentage of patients with HER2-positive and Triple Negative tumour underwent neoadjuvant treatment in clinical practice during the past 5 years out of total number of patients who underwent neoadjuvant treatment, regardless molecular subtypes. Secondary objectives The secondary objectives which are limited to molecular subtypes of study interest, HER2-positive and Triple Negative tumours, are follow reported:

* To perform a descriptive analysis on neoadjuvant treatment choice according to molecular subtype and initial staging;
* To perform a descriptive analysis on clinical and tumour pathological characteristics according to molecular subtypes and initial staging;
* To perform radiological response descriptive analysis achieved with neoadjuvant therapy according to treatment and instrumental examination type (for example: breast MRI, breast ultrasound or mammography);
* To perform a descriptive analysis of surgical procedures for both, the breast and the axilla, according to radiological tumour response, initial staging and molecular subtypes;
* To perform a descriptive analysis on therapies performed in adjuvant setting according to neoadjuvant treatment type, initial staging and molecular subtypes;
* To describe and to analyse the eligibility criteria evolution in neoadjuvant treatment setting during the last 5 years;
* To perform a descriptive analysis on pathological complete response (cPR) according to neoadjuvant treatment, molecular subtypes and initial staging;
* To evaluate disease-free survival (DFS) according to pCR and molecular subtypes;
* To evaluate overall survival (OS) according to pCR and molecular subtypes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For primary endpoint assessment we calculated the percentage of HER2 positive and Triple Negative patients who underwent neoadjuvant treatment in the past 5 years in each site. For this aim all patients with early breast cancer diagnosis who underwent neoadjuvant treatment during the study time, ranging from 01/01/2016 to 01/01/2021, will be included if they had:
* Histological diagnosis of infiltrating breast cancer performed by breast and/or axillary nodes biopsy;
* Age ≥ 18 years at the time of disease onset;
* Absence of secondary lesions, i.e. initial disease stage I, II or III;
* Known status of ER, PgR, HER-2 and Ki67.

Exclusion Criteria

* Documented distant disease at onset diagnosis or within 3 months from breast surgery;
* Prior neoadjuvant hormonal treatment exposure;
* Prior diagnosis of primary breast cancer or second primitive tumour starting from different organ
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alessandra Fabi

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A.Gemelli IRCCS, UOC Senologia

Antonella Palazzo

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A.Gemelli IRCCS, UOC Oncologia Medica

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS - Centro di Riferimento Oncologico (C.R.O.) di Aviano

Aviano, PN, Italy

Site Status ACTIVE_NOT_RECRUITING

AOU Ospedali Riuniti Torrette di Ancona

Ancona, , Italy

Site Status NOT_YET_RECRUITING

A.O.R.N. "San Giuseppe Moscati"

Avellino, , Italy

Site Status RECRUITING

Presidio di Brindisi Di Summa - Perrino

Brindisi, , Italy

Site Status NOT_YET_RECRUITING

Humanitas Istituto Clinico Catanese

Catania, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliera Universitaria "San Martino" - Istituto Nazionale per la Ricerca sul Cancro

Genova, , Italy

Site Status NOT_YET_RECRUITING

ASST - Azienda Ospedaliera Carlo Poma di Mantova

Mantova, , Italy

Site Status RECRUITING

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

Meldola, , Italy

Site Status RECRUITING

Istituto Europeo di Oncologia

Milan, , Italy

Site Status NOT_YET_RECRUITING

ASST - Ospedale Sacco

Milan, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliera Universitaria - P.O. di Modena

Modena, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliera "A. Cardarelli"

Napoli, , Italy

Site Status ACTIVE_NOT_RECRUITING

Istituto Nazionale Tumori di Napoli - IRCCS Istituto Pascale

Napoli, , Italy

Site Status RECRUITING

Universita' degli Studi di Napoli Federico II

Napoli, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara

Novara, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliero-Universitaria di Parma

Parma, , Italy

Site Status NOT_YET_RECRUITING

Azienda Ospedaliera Regionale San Carlo

Potenza, , Italy

Site Status NOT_YET_RECRUITING

Nuovo Ospedale di Prato - S. Stefano

Prato, , Italy

Site Status RECRUITING

Azienda Ospedaliera San Camillo Forlanini

Roma, , Italy

Site Status ACTIVE_NOT_RECRUITING

AOU Policlinico Umberto I

Roma, , Italy

Site Status NOT_YET_RECRUITING

Ospedale Sandro Pertini - ASL Roma 2

Roma, , Italy

Site Status NOT_YET_RECRUITING

Fondazione Policlinico A. Gemelli, IRCCS

Roma, , Italy

Site Status RECRUITING

Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, , Italy

Site Status RECRUITING

Fondazione Policlinico Universitario A. Gemelli

Roma, , Italy

Site Status RECRUITING

Arcispedale di Santo Spirito in Sassia - Nuovo Regina Margherita

Roma, , Italy

Site Status NOT_YET_RECRUITING

Azienda Socio Sanitaria Territoriale ( ASST ) della Valtellina e Alto Lario Presidio di Sondalo

Sondalo, , Italy

Site Status NOT_YET_RECRUITING

A.O.U. Città della salute e della scienza - Presidio Molinette

Torino, , Italy

Site Status NOT_YET_RECRUITING

APSS - Ospedale Santa Chiara di Trento

Trento, , Italy

Site Status NOT_YET_RECRUITING

Ospedale di Belcolle - Viterbo

Viterbo, , Italy

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alessandra Fabi, MD

Role: CONTACT

0630157337

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rossana Berardi, MD

Role: primary

Giuseppe Colantuoni, MD

Role: primary

0825203946

Laura Orlando, MD

Role: primary

0831537218

Michele Caruso, MD

Role: primary

Lucia Del Mastro, MD

Role: primary

010.5558904

Giovanna Catania, MD

Role: primary

Michela Palleschi, MD

Role: primary

0543 739297

Elisabetta Munzone, MD

Role: primary

02-57489.502

Nicla La Verde, MD

Role: primary

02 39042493

Luca Moscetti, MD

Role: primary

0594223244

MIchelino De Laurentiis, MD

Role: primary

081.5903699

Grazia Arpino, MD

Role: primary

0817463772/7251

Alessandra Gennari, MD

Role: primary

Antonino Musolino, MD

Role: primary

0521702660

Domenico Bilancia, MD

Role: primary

Laura Biganzoli, MD

Role: primary

0574 802528

Andrea Botticelli, MD

Role: primary

Teresa Gamucci, MD

Role: primary

Alessandra Fabi, MD

Role: primary

0630157337

Alessandra Fabi

Role: primary

+390630157337

Antonella Palazzo

Role: backup

Antonella Palazzo, MD

Role: primary

Simonetta Chiara Stani, MD

Role: primary

0668352073

Ornella Fusco, MD

Role: primary

Alessandra Beano, MD

Role: primary

Antonella Ferro, MD

Role: primary

0461903178

Agnese Fabbri, MD

Role: primary

0761339042 -055

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4946

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.